AtriCure, Inc. ATRC
56.26 USD -1.52 (-2.63%)
At closeNov 10, 2026, 4:00 PM EST
56.26 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
54.74 Day range 57.49
25.36 52-week range 66.02
- YTD
- +42.21%
- 1 year
- +75.87%
News
seekingalpha.com AtriCure, Inc. (ATRC) Presents at 2026 UBS Global Healthcare Conference Transcript AtriCure, Inc. ( ATRC ) 2026 UBS Global Healthcare Conference November 9, 2026 11:00 AM EST Company Participants Angela Wirick - Chief Financial Officer Conference Call Participants Patrick Andrew…
seekingalpha.com AtriCure: A New Quality Metric Could Put A Clip In Nearly Every Sternotomy AtriCure is shifting from targeting AF patients to all open-heart surgery patients, aiming for broader adoption as a preventive standard of care. Upcoming catalysts include the STS quality metric…
benzinga.com Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $67 Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $55 to $67.
benzinga.com Piper Sandler Reiterates Overweight on AtriCure, Raises Price Target to $70 Piper Sandler analyst Matt O'Brien reiterates AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $60 to $70.
benzinga.com Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts raised targets for FRSH, EW, ATRC, SUPN and DUOL; cut targets for FLG and AMD. EW was upgraded, while FLG was downgraded.
benzinga.com AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results AtriCure, Inc. (NASDAQ:ATRC) on Tuesday posted upbeat results for the third quarter.
benzinga.com AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results AtriCure beat Q3 estimates, raised FY2026 EPS and sales guidance, and saw analysts lift price targets to $70; shares fell 2%.
benzinga.com Needham Maintains Buy on AtriCure, Raises Price Target to $70 Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $64 to $70.
benzinga.com BTIG Maintains Buy on AtriCure, Raises Price Target to $70 BTIG analyst Marie Thibault maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $63 to $70.
benzinga.com AtriCure Q3 2026 Earnings Call Transcript AtriCure (NASDAQ:ATRC) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…- benzinga.com AtriCure Q3 Adj. EPS $0.17 Beats $(0.05) Estimate, Sales $154.450M Beat $151.217M Estimate AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $(0.05) by 440 percent. This is a 1800 percent increase over losses of $(0.01) per…
benzinga.com AtriCure Raises FY2026 Adj EPS Guidance from $0.24-$0.32 to $0.40-$0.46 vs $0.15 Est; Raises FY2026 Sales Guidance from $602.000M-$610.000M to $606.000M-$610.000M vs $606.219M Est AtriCure (NASDAQ:ATRC) raises FY2026 Adj EPS guidance from $0.24-$0.32 to $0.40-$0.46 vs $0.15 analyst estimate. Raises FY2026 sales outlook from $602.000 million-$610.000 million to $606.000…- benzinga.com Citizens Maintains Market Outperform on AtriCure, Raises Price Target to $68 Citizens analyst Daniel Stauder maintains AtriCure (NASDAQ:ATRC) with a Market Outperform and raises the price target from $52 to $68.
benzinga.com BTIG Maintains Buy on AtriCure, Raises Price Target to $63 BTIG analyst Ryan Zimmerman maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $55 to $63.